The Drive to ‘25
The drive to 2025 is underway! With 2023 in the rear-view mirror, we at EpicentRx look ahead not only to 2024 but also to 2025 when we expect top-line data from five key EpicentRx clinical trials to read out. For lead FDA Fast Tracked small molecule, RRx-001...
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors
Age of posterity: Anti-inflammaging – a very modern dichotomy